Notice2024-13534
Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 21, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 120 (Friday, June 21, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52022]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-13534]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-34-2024]
Foreign-Trade Zone (FTZ) 29, Notification of Proposed Production
Activity; Catalent Pharma Solutions, LLC (Catalent); (Nonsteroidal
Antiandrogen Tablets); Winchester, Kentucky
Catalent submitted a notification of proposed production activity
to the FTZ Board (the Board) for its facility in Winchester, Kentucky
within FTZ 29. The notification conforming to the requirements of the
Board's regulations (15 CFR 400.22) was received on June 11, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products include: nonsteroidal antiandrogen
tablets (duty-free).
The proposed foreign-status materials/components include:
apalutamide (active pharmaceutical ingredient) (duty rate of 6.5%).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#9ef8eae4deeaecfffafbb0f9f1e8"><span class="__cf_email__" data-cfemail="395f4d43794d4b585d5c175e564f">[email protected]</span></a>. The closing period for their receipt is July 31, 2024.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Kolade Osho at
<a href="/cdn-cgi/l/email-protection#347f5b585550511a7b475c5b7440465550511a535b42"><span class="__cf_email__" data-cfemail="703b1f1c1114155e3f03181f3004021114155e171f06">[email protected]</span></a>.
Dated: June 14, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-13534 Filed 6-20-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 21, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.